Siemens

The company said it has production capacity for more than 50 million tests per month and that its high-throughput analyzers can deliver up to 440 tests per hour. 

The company said it is targeting production of more than 50 million tests per month, which can run on 20,000 globally installed Siemens systems.

Siemens Healthineers got the nod for its Advia Centaur CA 125 II Assay for detecting CA 125 to help in the management of patients with ovarian carcinoma.

The company had received CE marking for the test in April, allowing for its use as a clinical diagnostic test in Europe.

The firm said it anticipates introducing an antibody test for its high-throughput analyzers that will detect an immune response to the coronavirus.

The company plans to ship more than 1.3 million tests per month worldwide as production capacity increases in May.

BioMérieux's BioFire received clearance for its Blood Culture Identification 2 Panel for the identification of nucleic acids associated with bacteria and yeast.

The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.

The analyzer supports COVID-19 response efforts, where blood-gas testing plays a critical role in monitoring patients' respiratory distress, the firm said.